{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:49:44Z","timestamp":1793681384415,"version":"4.5.1"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"\n Importance<\/jats:title>\n Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and psychotherapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n In this double-blind randomized clinical trial, participants were offered 12 weeks of manualized psychotherapy and were randomly assigned to receive psilocybin vs diphenhydramine during 2 day-long medication sessions at weeks 4 and 8. Outcomes were assessed over the 32-week double-blind period following the first dose of study medication. The study was conducted at 2 academic centers in the US. Participants were recruited from the community between March 12, 2014, and March 19, 2020. Adults aged 25 to 65 years with a\n DSM-IV<\/jats:italic>\n diagnosis of alcohol dependence and at least 4 heavy drinking days during the 30 days prior to screening were included. Exclusion criteria included major psychiatric and drug use disorders, hallucinogen use, medical conditions that contraindicated the study medications, use of exclusionary medications, and current treatment for AUD.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Study medications were psilocybin, 25 mg\/70 kg, vs diphenhydramine, 50 mg (first session), and psilocybin, 25-40 mg\/70 kg, vs diphenhydramine, 50-100 mg (second session). Psychotherapy included motivational enhancement therapy and cognitive behavioral therapy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was percentage of heavy drinking days, assessed using a timeline followback interview, contrasted between groups over the 32-week period following the first administration of study medication using multivariate repeated-measures analysis of variance.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 95 participants (mean [SD] age, 46 [12] years; 42 [44.2%] female) were randomized (49 to psilocybin and 46 to diphenhydramine). One participant (1.1%) was American Indian\/Alaska Native, 3 (3.2%) were Asian, 4 (4.2%) were Black, 14 (14.7%) were Hispanic, and 75 (78.9%) were non-Hispanic White. Of the 95 randomized participants, 93 received at least 1 dose of study medication and were included in the primary outcome analysis. Percentage of heavy drinking days during the 32-week double-blind period was 9.7% for the psilocybin group and 23.6% for the diphenhydramine group, a mean difference of 13.9%; (95% CI, 3.0\u201324.7;\n F<\/jats:italic>\n 1,86<\/jats:sub>\n \u2009=\u20096.43;\n P<\/jats:italic>\n \u2009=\u2009.01). Mean daily alcohol consumption (number of standard drinks per day) was also lower in the psilocybin group. There were no serious adverse events among participants who received psilocybin.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Psilocybin administered in combination with psychotherapy produced robust decreases in percentage of heavy drinking days over and above those produced by active placebo and psychotherapy. These results provide support for further study of psilocybin-assisted treatment for AUD.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02061293<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2022.2096","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T11:32:19Z","timestamp":1661340739000},"page":"953","source":"Crossref","is-referenced-by-count":697,"title":["Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder"],"prefix":"10.1001","volume":"79","author":[{"given":"Michael P.","family":"Bogenschutz","sequence":"first","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa A.","family":"Forcehimes","sequence":"additional","affiliation":[{"name":"The Change Companies, Carson City, Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Laska","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"},{"name":"Department of Population Health, Division of Biostatistics, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Mennenga","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey T.","family":"Owens","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"},{"name":"Department of Psychology, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Podrebarac","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, New York University Langone Center for Psychedelic Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Tonigan","sequence":"additional","affiliation":[{"name":"University of New Mexico Center on Alcohol, Substance Use and Addictions, Albuquerque"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Worth","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"yoi220046r1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"12","key":"yoi220046r2","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"3","key":"yoi220046r3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"11","key":"yoi220046r4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"issue":"15","key":"yoi220046r5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression.","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"yoi220046r6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"yoi220046r7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi220046r8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"yoi220046r9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression.","volume":"28","author":"Daws","year":"2022","journal-title":"Nat Med"},{"key":"yoi220046r10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behav Brain Res"},{"issue":"2","key":"yoi220046r11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens.","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther"},{"issue":"11","key":"yoi220046r12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","article-title":"Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics.","volume":"42","author":"Aleksandrova","year":"2021","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"yoi220046r13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.","volume":"11","author":"Doss","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"3","key":"yoi220046r14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics.","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol Rev"},{"issue":"4","key":"yoi220046r15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","article-title":"Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning.","volume":"228","author":"Catlow","year":"2013","journal-title":"Exp Brain Res"},{"key":"yoi220046r16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.800072","article-title":"Psychedelic therapy\u2019s transdiagnostic effects: a research domain criteria (RDoC) perspective.","volume":"12","author":"Kelly","year":"2021","journal-title":"Front Psychiatry"},{"key":"yoi220046r17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","article-title":"Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.","volume":"142","author":"Roseman","year":"2018","journal-title":"Neuropharmacology"},{"issue":"47","key":"yoi220046r18","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2399","article-title":"Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism.","volume":"7","author":"Meinhardt","year":"2021","journal-title":"Sci Adv"},{"issue":"2","key":"yoi220046r19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","article-title":"Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression.","volume":"34","author":"Mertens","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"4","key":"yoi220046r20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1055\/a-1341-1907","article-title":"Classical psychedelics as therapeutics in psychiatry\u2014current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders.","volume":"54","author":"Mertens","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"yoi220046r21","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin.","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci Rep"},{"issue":"16","key":"yoi220046r22","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1017\/S003329172000389X","article-title":"Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.","volume":"50","author":"Goldberg","year":"2020","journal-title":"Psychol Med"},{"issue":"7","key":"yoi220046r23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1021\/acschemneuro.8b00134","article-title":"Effects of N, N-dimethyltryptamine on rat behaviors relevant to anxiety and depression.","volume":"9","author":"Cameron","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"16","key":"yoi220046r24","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"issue":"17","key":"yoi220046r25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"yoi220046r26","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression.","volume":"8","author":"Roseman","year":"2018","journal-title":"Front Pharmacol"},{"key":"yoi220046r27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","article-title":"Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.","volume":"15","author":"Davis","year":"2020","journal-title":"J Contextual Behav Sci"},{"issue":"3","key":"yoi220046r28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr Drug Abuse Rev"},{"issue":"2","key":"yoi220046r29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects.","volume":"4","author":"Yaden","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"yoi220046r30","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-12184-5","article-title":"Psychedelic-assisted therapy for substance use disorders and potential mechanisms of action.","author":"Rieser","year":"2021","journal-title":"Curr Top Behav Neurosci"},{"key":"yoi220046r31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression.","volume":"12","author":"Murphy","year":"2022","journal-title":"Front Pharmacol"},{"issue":"6","key":"yoi220046r32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/17512433.2020.1772054","article-title":"Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.","volume":"13","author":"Greenway","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"yoi220046r33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","article-title":"A controlled study of lysergide in the treatment of alcoholism. I. the effects on drinking behavior.","volume":"27","author":"Smart","year":"1966","journal-title":"Q J Stud Alcohol"},{"issue":"10","key":"yoi220046r34","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics.","volume":"125","author":"Hollister","year":"1969","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi220046r35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1176\/ajp.126.1.59","article-title":"A clinical study of LSD treatment in alcoholism.","volume":"126","author":"Ludwig","year":"1969","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi220046r36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00005053-197002000-00003","article-title":"Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study.","volume":"150","author":"Bowen","year":"1970","journal-title":"J Nerv Ment Dis"},{"issue":"11","key":"yoi220046r37","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","article-title":"The experimental use of psychedelic (LSD) psychotherapy.","volume":"212","author":"Pahnke","year":"1970","journal-title":"JAMA"},{"issue":"4","key":"yoi220046r38","doi-asserted-by":"publisher","first-page":"932","DOI":"10.15288\/qjsa.1970.31.932","article-title":"Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation.","volume":"31","author":"Tomsovic","year":"1970","journal-title":"Q J Stud Alcohol"},{"issue":"7","key":"yoi220046r39","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"yoi220046r41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0022167816673493","article-title":"Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism.","volume":"57","author":"Bogenschutz","year":"2016","journal-title":"J Humanist Psychol"},{"issue":"3","key":"yoi220046r42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"yoi220046r46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/add.1988.83.issue-4","article-title":"Reliability of a timeline method: assessing normal drinkers\u2019 reports of recent drinking and a comparative evaluation across several populations.","volume":"83","author":"Sobell","year":"1988","journal-title":"Br J Addict"},{"issue":"1","key":"yoi220046r47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0376-8716(96)01263-X","article-title":"The reliability of the Alcohol Timeline Followback when administered by telephone and by computer.","volume":"42","author":"Sobell","year":"1996","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"yoi220046r48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamapsychiatry.2018.3079","article-title":"Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials.","volume":"76","author":"Falk","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"23","key":"yoi220046r51","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1001\/jama.2017.18556","article-title":"Guidelines for the content of statistical analysis plans in clinical trials.","volume":"318","author":"Gamble","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"yoi220046r52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"MICE: Multivariate Imputation by Chained Equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"yoi220046r40","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition","author":"First","year":"1997"},{"key":"yoi220046r43","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biological Methods","author":"Sobell","year":"1992"},{"key":"yoi220046r44","volume-title":"Timeline Follow Back: A Calendar Method for Assessing Alcohol and Drug Use (User\u2019s Guide)","author":"Sobell","year":"1996"},{"key":"yoi220046r45","volume-title":"Alcoholism: Developing Drugs for Treatment: Guidance for Industry","author":"Center for Drug Evaluation and Research","year":"2015"},{"key":"yoi220046r49","volume-title":"International Guide for Monitoring Alcohol Consumption and Related Harm","author":"World Health Organization","year":"2000"},{"key":"yoi220046r50","volume-title":"The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse: Test Manual","author":"Miller","year":"1995"},{"key":"yoi220046r53","volume-title":"Applied multivariate statistics for the social sciences","author":"Stevens","year":"2002"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2795625\/jamapsychiatry_bogenschutz_2022_oi_220046_1664208846.29988.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T11:01:46Z","timestamp":1664967706000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2795625"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.7554\/eLife.104006.2","asserted-by":"object"}]},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}